{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:31:35Z","timestamp":1792859495391,"version":"4.5.0"},"reference-count":55,"publisher":"Informa UK Limited","issue":"29","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo, Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.2217\/fon-2020-0542","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T11:40:16Z","timestamp":1595504416000},"page":"2345-2356","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":47,"title":["Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor"],"prefix":"10.1080","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-8636","authenticated-orcid":false,"given":"Hans","family":"Gelderblom","sequence":"first","affiliation":[{"name":"Leiden University Medical Center,\rLeiden,\rNetherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel van","family":"de Sande","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center,\rLeiden,\rNetherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"e_1_3_3_3_1","first-page":"100","volume-title":"World Health Organization Classification of Tumours of Soft Tissue and Bone.","author":"de Saint Aubain Somerhausen N","year":"2013","unstructured":"de Saint Aubain Somerhausen N , vande Rijn M. Tenosynovial giant cell tumour: localized type, diffuse type. In: World Health Organization Classification of Tumours of Soft Tissue and Bone.FletcherCDM, BridgeJA, HogendoornPCW, MartensF. (Eds). 100\u2013103IARC Press, Lyon, France (2013)."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198005000-00004"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17453674.2017.1361126"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160816"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.04.022"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-015-0385-x"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.2196\/ijmr.9325"},{"key":"e_1_3_3_10_1","first-page":"S866","article-title":"Health-related quality of life in tenosynovial giant cell tumor (TGCT) patients in Europe and US: an observational disease registry","volume":"22","author":"Lopez-Bastida J","year":"2019","unstructured":"Lopez-Bastida J , YeX, LaeisPet al. Health-related quality of life in tenosynovial giant cell tumor (TGCT) patients in Europe and US: an observational disease registry. CTOS22, S866 (2019).","journal-title":"CTOS"},{"key":"e_1_3_3_11_1","unstructured":"von Mehren M KaneJMI BenjaminRSet al. NCCN Clinical Practice Guidelines in Soft Tissue Sarcoma. Version 4.2019 (2019). www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-016-0060-4"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy321"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.03.008"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328347e1e3"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411366"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26409"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30143-8"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30100-7"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e18737"},{"key":"e_1_3_3_21_1","unstructured":"Daiichi-Sankyo Company Limited\n. TURALIO\u2122 full prescribing information (2020). https:\/\/dsi.com\/prescribing-information-portlet\/getPIContent?productName=Turalio&inline=true"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0507321103"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2576"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0866"},{"key":"e_1_3_3_25_1","volume-title":"Presented at: Tenth American Conference on Pharmacometrics (ACoP10).","author":"Yin O FJ","year":"2019","unstructured":"Yin O FJ , PolhamusD, ZahirHet al. Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor (TGCT). Presented at: Tenth American Conference on Pharmacometrics (ACoP10).FL, USA (2019). Poster W-017."},{"key":"e_1_3_3_26_1","volume-title":"Presented at: Tenth American Conference on Pharmacometrics (ACoP10).","author":"Yin O","year":"2019","unstructured":"Yin O , KangJ, KnebelWet al. Population pharmacokinetic analysis of pexidartinib in healthy subjects and patients with tenosynovial giant cell tumor (TGCT) or other solid tumors. Presented at: Tenth American Conference on Pharmacometrics (ACoP10).FL, USA (2019). Poster M-028."},{"key":"e_1_3_3_27_1","volume-title":"Presented at: 2019 Connective Tissue Oncology Society (CTOS) Annual Meeting.","author":"Lin C-C","year":"2019","unstructured":"Lin C-C , GuoJ, TapWDet al. Population pharmacokinetic analysis for comparison of pexidartinib exposure in Asian and non-Asian patients. Presented at: 2019 Connective Tissue Oncology Society (CTOS) Annual Meeting.Tokyo, Japan (2019). Abstract 3253949."},{"key":"e_1_3_3_28_1","volume-title":"Presented at: Orthopaedic Research Society Annual Meeting 2015.","author":"Peterfy C","year":"2015","unstructured":"Peterfy C , TapWD, DiCarloJet al. MRI assessment of oral CSF1 receptor inhibition with PLX3397 for tenosynovial giant cell tumor using novel modified RECIST, tumor volume scoring and tissue damage scoring methods. Presented at: Orthopaedic Research Society Annual Meeting 2015.NV, USA (2015). Poster 2028."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30764-0"},{"key":"e_1_3_3_30_1","volume-title":"Presented at: 2019 Connective Tissue Oncology Society (CTOS) Annual Meeting.","author":"Tap WD","year":"2019","unstructured":"Tap WD , GelhornHL, YeXet al. Improvement in patient-reported pain in a Phase iii trial of pexidartinib (PLX3397) among patients with tenosynovial giant cell tumor (TGCT). Presented at: 2019 Connective Tissue Oncology Society (CTOS) Annual Meeting.Tokyo, Japan (2019)."},{"key":"e_1_3_3_31_1","volume-title":"Presented at: 2019 European Musculo-Skeletal Oncology Society (EMSOS) Annual Meeting.","author":"van de Sande M","year":"2019","unstructured":"van de Sande M , StaalsE, GronchiAet al. Pexidartinib for advanced tenosynovial giant cell tumor: patient subgroup results from the Phase 3 ENLIVEN study. Presented at: 2019 European Musculo-Skeletal Oncology Society (EMSOS) Annual Meeting.Florence, Italy (2019). Abstract 2250."},{"key":"e_1_3_3_32_1","volume-title":"Presented at: 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.","author":"Gelderblom H","year":"2019","unstructured":"Gelderblom H , TapWD, PalmeriniEet al. Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): long-term efficacy and safety from the Phase 3 ENLIVEN and Phase 1 PLX108-01 (TGCT cohort) studies. Presented at: 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.IL, USA (2019). Abstract 11042."},{"key":"e_1_3_3_33_1","volume-title":"Presented at: 2019 Musculo Skeletal Tumor Society (MSTS) Annual Meeting.","author":"Healey JH","year":"2019","unstructured":"Healey JH , GelderblomH, WagnerAJet al. Pexidartinib for locally advanced tenosynovial giant cell tumor (TGCT): overall long-term pooled efficacy and safety with characterization of hepatic adverse reactions (ARs) from ENLIVEN and other studies. Presented at: 2019 Musculo Skeletal Tumor Society (MSTS) Annual Meeting.OR, USA (2019). Presentation 46."},{"key":"e_1_3_3_34_1","volume-title":"Presented at: 2019 Connective Tissue Oncology Society (CTOS) Annual Meeting.","author":"Healey JH","year":"2019","unstructured":"Healey JH , GelderblomH, WagnerAJet al. Pexidartinib for locally advanced tenosynovial giant cell tumor: overall long-term pooled efficacy and safety with characterization of hepatic adverse reactions from ENLIVEN and other studies. Presented at: 2019 Connective Tissue Oncology Society (CTOS) Annual Meeting.Tokyo, Japan (2019). Abstract 3208650."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov245"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.2015"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919854238"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.11055"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0418"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.11509"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.10546"},{"key":"e_1_3_3_42_1","volume-title":"Presented at: 2019 American College of Clinical Pharmacology (ACCP) Annual Meeting.","author":"Zahir H","year":"2019","unstructured":"Zahir H , DarpoB, GuXet al. A concentration-QTc analysis to determine the effect of pexidartinib on the QTc interval. Presented at: 2019 American College of Clinical Pharmacology (ACCP) Annual Meeting.IL, USA (2019).Poster 073."},{"key":"e_1_3_3_43_1","volume-title":"Presented at: ESMO Congress 2019.","author":"Bauer S","year":"2019","unstructured":"Bauer S , LewisJH HG, vande Sande Met al. Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumour (TGCT): characterization of hepatic adverse reactions (ARs). Presented at: ESMO Congress 2019.Barcelona, Spain (2019).Poster 1696P."},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.03.029"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0257-y"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0112-z"},{"key":"e_1_3_3_47_1","unstructured":"ClinicalTrials.gov\n. A Phase I study to assess safety pharmacokinetics and pharmacodynamics of PLX3397 in patients with advanced incurable solid tumors in which the target kinases are linked to disease pathophysiology. ClinicalTrials.gov number NCT01004861. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01004861"},{"key":"e_1_3_3_48_1","unstructured":"ClinicalTrials.gov\n. Phase 3 study of pexidartinib for pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS) (ENLIVEN). ClinicalTrials.gov number NCT02371369. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02371369"},{"key":"e_1_3_3_49_1","unstructured":"ClinicalTrials.gov\n. Tenosynovial giant cell tumors (TGCT) observational platform project (TOP). ClinicalTrials.gov number NCT02948088. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02948088"},{"key":"e_1_3_3_50_1","unstructured":"ClinicalTrials.gov\n. PLX3397 KIT in Acral aNd mucOsal Melanoma (PIANO). ClinicalTrials.gov number NCT02071940. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02071940"},{"key":"e_1_3_3_51_1","unstructured":"ClinicalTrials.gov\n. Evaluation of safety and activity of an anti-PDL1 antibody (DURVALUMAB) combined with CSF-1R TKI (PEXIDARTINIB) in patients with metastatic\/advanced pancreatic or colorectal cancers (MEDIPLEX). ClinicalTrials.gov number NCT02777710. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02777710"},{"key":"e_1_3_3_52_1","unstructured":"ClinicalTrials.gov\n. PLX3397 in children and young adults with refractory leukemias and refractory solid tumors including neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN). ClinicalTrials.gov number NCT02390752. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02390752"},{"key":"e_1_3_3_53_1","unstructured":"ClinicalTrials.gov\n. Phase Ib\/II study of PLX 3397 and eribulin in patients with metastatic breast cancer. ClinicalTrials.gov number NCT01596751. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01596751"},{"key":"e_1_3_3_54_1","unstructured":"ClinicalTrials.gov\n. A Phase 1b\/2 study of PLX3397 + radiation therapy + temozolomide in patients with newly diagnosed glioblastoma. ClinicalTrials.gov number NCT01790503. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01790503"},{"key":"e_1_3_3_55_1","unstructured":"ClinicalTrials.gov\n. PLX3397 plus sirolimus in unresectable sarcoma and malignant peripheral nerve sheath tumors (PLX3397). ClinicalTrials.gov number NCT02584647. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02584647"},{"key":"e_1_3_3_56_1","unstructured":"ClinicalTrials.gov\n. PLX9486 as a single agent and in combination with PLX3397 or PLX9486 with sunitinib in patients with advanced solid tumors. ClinicalTrials.gov number NCT02401815. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02401815"},{"key":"e_1_3_3_57_1","unstructured":"ClinicalTrials.gov\n. A study of MEK162 (Binimetinib) in combination with pexidartinib in patients with advanced gastrointestinal stromal tumor (GIST). ClinicalTrials.gov number NCT03158103. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03158103"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-0542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:15Z","timestamp":1719125175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-0542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":55,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.2217\/fon-2020-0542"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-0542","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}